Loading
A phase 2/3 trial of Visugromab, run by CatalYm GmbH, now recruiting.
Visugromab in Cachexia International Trial is a phase 2/3 interventional study registered as NCT07112196 by CatalYm GmbH, with 518 participants planned, started 2026-04-16. Conditions listed: Cancer-associated Cachexia. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Visugromab, CatalYm, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Shares Visugromab, CatalYm, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/